On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
ORGANIZATION
First Time FPMAJ’s Supply Coordination Scheme Invoked for 13 APIs Tied to Kobayashi Kako
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) has launched its supply coordination scheme for the first time, covering 13 APIs for which shortage concerns have arisen after a spate of recalls and shipment curbs attributed to Kobayashi Kako’s…
To read the full story
Related Article
- Kobayashi Kako Expected to Face Administrative Penalty This Fiscal Year, Biz Suspension Likely
January 12, 2021
- Kobayashi Kako Adds 2 APIs to Class II Recall List, Meiji/Elmed Products
December 28, 2020
- Kobayashi Kako Recalls 12 More APIs after On-Site Inspections
December 25, 2020
- Results of On-Site Probe into Kobayashi Kako Due Out Early Next Year, MHLW Eyes Biz Suspension
December 24, 2020
- 2nd Death Reported for Tainted Itraconazole User, Doctor Says Causal Link Unlikely
December 18, 2020
- Kobayashi Kako Manually Managed Itraconazole Production; Hand-Written Record on Rilmazafone Mix-Up Found
December 17, 2020
- Kobayashi Kako Temporary Halts Shipments of All Products after Tainted Itraconazole Issue
December 15, 2020
- 1st Death Reported for Kobayashi Kako’s Tainted Itraconazole Product
December 14, 2020
- Kobayashi Kako Recalls Trigger Shipment Control for Kaken's Itraconazole Product
December 11, 2020
- Pharmacist Group Chief Appalled at Itraconazole Recalls; 84 Cases of Health Damages Reported
December 10, 2020
- With Contaminated Itraconazole, Patients Might Have Taken Sleep Inducer at 10-20 Times Regular Dosage
December 9, 2020
- Kobayashi Kako Launches Another Recall for Itraconazole, Class II This Time
December 8, 2020
- Kobayashi Kako Recalls Itraconazole over Hypnotic Contamination; Side Effects Confirmed
December 7, 2020
ORGANIZATION
- Generic Use Targets Should Be Set by City/Ward in Major Prefectures: Professor
January 14, 2021
- Yaz Generics to Carry Single Brand Name of DroEthi
January 13, 2021
- JPMA Chief Vows Renewed Efforts to Deliver COVID-19 Drugs, Vaccines as Japan Declares 2nd Emergency
January 12, 2021
- Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
- 5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing
January 5, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…